First Trust Advisors LP Acquires 335,564 Shares of ADMA Biologics Inc $ADMA

First Trust Advisors LP boosted its holdings in shares of ADMA Biologics Inc (NASDAQ:ADMA) by 1,361.1% in the first quarter, HoldingsChannel reports. The fund owned 360,217 shares of the biotechnology company’s stock after acquiring an additional 335,564 shares during the period. First Trust Advisors LP’s holdings in ADMA Biologics were worth $3,246,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of the business. Calamos Advisors LLC boosted its position in shares of ADMA Biologics by 120.0% in the 4th quarter. Calamos Advisors LLC now owns 292,426 shares of the biotechnology company’s stock worth $5,334,000 after purchasing an additional 159,501 shares in the last quarter. Louisiana State Employees Retirement System purchased a new position in ADMA Biologics during the first quarter valued at $951,000. BNP Paribas Financial Markets boosted its holdings in ADMA Biologics by 2,188.4% in the fourth quarter. BNP Paribas Financial Markets now owns 1,141,106 shares of the biotechnology company’s stock worth $20,814,000 after acquiring an additional 1,091,241 shares in the last quarter. Y Intercept Hong Kong Ltd boosted its holdings in ADMA Biologics by 1,508.1% in the first quarter. Y Intercept Hong Kong Ltd now owns 1,075,422 shares of the biotechnology company’s stock worth $9,690,000 after acquiring an additional 1,008,548 shares in the last quarter. Finally, Next Century Growth Investors LLC grew its stake in shares of ADMA Biologics by 178.3% in the fourth quarter. Next Century Growth Investors LLC now owns 1,100,773 shares of the biotechnology company’s stock worth $20,078,000 after acquiring an additional 705,217 shares during the last quarter. Institutional investors own 75.68% of the company’s stock.

Analyst Upgrades and Downgrades

ADMA has been the subject of several recent analyst reports. Zacks Research lowered ADMA Biologics from a “hold” rating to a “strong sell” rating in a research report on Tuesday. Wall Street Zen downgraded shares of ADMA Biologics from a “buy” rating to a “hold” rating in a research report on Monday, May 4th. Canaccord Genuity Group reduced their price objective on shares of ADMA Biologics from $21.00 to $18.00 and set a “buy” rating for the company in a research note on Thursday, May 7th. Raymond James Financial began coverage on shares of ADMA Biologics in a report on Wednesday, June 10th. They issued an “outperform” rating and a $21.00 target price for the company. Finally, Mizuho dropped their target price on shares of ADMA Biologics from $20.00 to $17.00 and set an “outperform” rating on the stock in a research note on Wednesday, July 15th. Three research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $18.67.

ADMA Biologics News Summary

Here are the key news stories impacting ADMA Biologics this week:

• Positive Sentiment: Strong earnings and ASCENIV growth: Second-quarter adjusted EPS of $0.16 matched consensus, while revenue reached $124.4 million. ASCENIV revenue rose 24% year over year to $102.9 million, GAAP net income increased 11% to $37.8 million, and adjusted EBITDA grew 22% to $61.8 million. ADMA Biologics Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Guidance maintained and buybacks planned: ADMA reiterated its 2026 revenue outlook of $530 million to $560 million, broadly consistent with analyst expectations, and is targeting more than $200 million in share repurchases. Management said accelerating ASCENIV demand should offset continued weakness in BIVIGAM. ADMA Reiterates 2026 Guidance and Share Repurchase Target
• Neutral Sentiment: BIVIGAM remains a concern: Quarterly revenue slightly missed expectations, at $124.4 million versus approximately $125.3 million expected, as BIVIGAM demand remained under pressure despite sequential stabilization. The company’s outlook assumes ASCENIV growth will compensate for that weakness. ADMA Q2 Earnings Meet, Revenues Miss on BIVIGAM Weakness
• Negative Sentiment: Legal overhang intensifies: Multiple law firms publicized a securities-fraud class action and an August 10 lead-plaintiff deadline for investors who bought shares between August 9, 2024, and March 25, 2026. The complaints allege misrepresentations involving financial condition, revenue recognition, inventory distribution, and business practices; these allegations have not been established in court. ADMA Investor Alert
• Negative Sentiment: Analyst downgrade: Zacks Research downgraded ADMA from “hold” to “strong sell,” adding pressure to sentiment even though the company met EPS expectations and maintained its outlook.

Insider Transactions at ADMA Biologics

In related news, Director Jerrold B. Grossman purchased 12,500 shares of the company’s stock in a transaction dated Monday, May 11th. The shares were purchased at an average price of $8.01 per share, with a total value of $100,125.00. Following the acquisition, the director directly owned 513,884 shares in the company, valued at $4,116,210.84. The trade was a 2.49% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 3.90% of the company’s stock.

ADMA Biologics Stock Up 8.6%

ADMA stock opened at $10.06 on Friday. The stock has a market capitalization of $2.33 billion, a P/E ratio of 14.37 and a beta of 0.74. The company has a debt-to-equity ratio of 0.51, a current ratio of 6.95 and a quick ratio of 3.93. ADMA Biologics Inc has a 1-year low of $7.21 and a 1-year high of $20.46. The business has a fifty day moving average price of $8.59 and a 200-day moving average price of $11.32.

ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.16 EPS for the quarter, meeting the consensus estimate of $0.16. ADMA Biologics had a return on equity of 39.60% and a net margin of 32.98%.The company had revenue of $124.39 million for the quarter, compared to analysts’ expectations of $125.34 million. During the same period last year, the firm posted $0.14 earnings per share. ADMA Biologics’s revenue was up 2.0% compared to the same quarter last year. Equities analysts forecast that ADMA Biologics Inc will post 0.8 earnings per share for the current fiscal year.

ADMA Biologics Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.